Mylan Laboratories News

A jury in U.S. District Cout in Delaware ruled against Mylan Inc. and its subsidiaries, Mylan Pharmaceuticals, Dey Inc.

Mylan Inc. Intends to Challenge Unfavorable Verdict in Patent Trial Related to Mylan 's Generic Version of Sunovion's Xopenex Inhalation Solution /PRNewswire/ -- Mylan Inc.

Mylan Inc. today announced that a jury has rendered an unfavorable verdict in a patent infringement lawsuit filed by Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., against Mylan Inc., Mylan Pharmaceuticals Inc., Dey Inc.

Mylan Pharmaceuticals has gotten federal approval for a generic version of Mayne Pharma's Doryx but agreed not to bring the drug to market until after a patent-infringement lawsuit concludes.

Alex Nixon is a Pittsburgh Tribune-Review staff writer and can be reached at 412-320-7928, via e-mail or on Twitter.

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

The Subcommittee on Health will hold a hearing on Thursday, February 9, 2012, at 10:00 a.m. in room 2123 of the Rayburn House Office Building, entitled "Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages." Panel 2 Ms.

Mylan 's stock had its "strong-buy" rating reiterated by equities research analysts at Needham & Company in a research note issued to investors on Monday.

Mylan said it had received the abbreviated new drug application for Clindamycin Phosphate/Benzoyl Peroxide Gel, the generic version of BenzaClin that treats acne.

Valeant Pharmaceuticals International, Inc. today announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel , a generic version of Benzaclin, and 5% fluorouracil cream, , an authorized generic of Efudex, to Mylan Inc.

The trailing-twelve-month operating margin at Hi-Tech Pharmacal Co Inc is 33.13%. HITK's revenue for the same period is $219.97 million.

CANONSBURG Southpointe-based Mylan Inc. said Thursday that its Mylan Laboratories Ltd.

Amazon.com Inc. : BGC Financial lowered its estimates and price target for Amazon.com to reflect the company's slowing revenue growth and profit decline in Q4.

For investors concerned about the macroeconomy, biotechnology provides some of the safest plays.

Prescription drug manufacturers Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc.

From high dividend yields to low betas, biotech provides some of the strongest risk/reward opportunities.

Executive Chairman Robert Coury , CEO Heather Bresch , President Rajiv Malik , COO Hal Korman , CFO John Sheehan and other executives will host an investor day Feb.

Mylan Inc. will issue its fourth-quarter and full-year 2011 earnings results before the market opens Feb.

Mylan was upgraded by Zacks Investment Research from a "neutral" rating to an "outperform" rating in a report issued on Monday.

According to GuruFocus Insider Data , these are the largest insider sells during the past week.